Literature DB >> 34817935

Prevalence of hepatitis D virus co-infection in Austria - Finding the needle in the haystack.

Milan J Sonneveld1, Benjamin Maasoumy2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34817935      PMCID： PMC8672078          DOI： 10.1002/ueg2.12177

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN： 2050-6406            Impact factor:   4.623


× No keyword cloud information.
  15 in total

1.  Editorial: rapid disease progression in hepatitis delta-can we turn the tide?

Authors:  Milan J Sonneveld; Robert J de Knegt
Journal:  Aliment Pharmacol Ther       Date:  2020-01       Impact factor: 8.171

2.  Antiviral treatment and liver-related complications in hepatitis delta.

Authors:  Anika Wranke; Beatriz Calle Serrano; Benjamin Heidrich; Janina Kirschner; Birgit Bremer; Patrick Lehmann; Svenja Hardtke; Katja Deterding; Kerstin Port; Max Westphal; Michael P Manns; Markus Cornberg; Heiner Wedemeyer
Journal:  Hepatology       Date:  2016-11-30       Impact factor: 17.425

3.  Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia.

Authors:  Adriana Palom; Sergio Rodríguez-Tajes; Carmen A Navascués; Javier García-Samaniego; Mar Riveiro-Barciela; Sabela Lens; Manuel Rodríguez; Rafael Esteban; Maria Buti
Journal:  Aliment Pharmacol Ther       Date:  2019-11-13       Impact factor: 8.171

Review 4.  Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Authors:  Cihan Yurdaydin; Zaigham Abbas; Maria Buti; Markus Cornberg; Rafael Esteban; Ohad Etzion; Edward J Gane; Robert G Gish; Jeffrey S Glenn; Saeed Hamid; Theo Heller; Christopher Koh; Pietro Lampertico; Yoav Lurie; Michael Manns; Raymundo Parana; Mario Rizzetto; Stephan Urban; Heiner Wedemeyer
Journal:  J Hepatol       Date:  2018-12-27       Impact factor: 25.083

5.  Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.

Authors:  Alessandro Loglio; Peter Ferenci; Sara Colonia Uceda Renteria; Christine Y L Tham; Florian van Bömmel; Marta Borghi; Heidemarie Holzmann; Riccardo Perbellini; Elena Trombetta; Silvia Giovanelli; Letizia Greco; Laura Porretti; Daniele Prati; Ferruccio Ceriotti; Giovanna Lunghi; Antonio Bertoletti; Pietro Lampertico
Journal:  J Hepatol       Date:  2019-07-11       Impact factor: 25.083

6.  Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.

Authors:  Adriaan J van der Meer; Jordan J Feld; Harald Hofer; Piero L Almasio; Vincenza Calvaruso; Conrado M Fernández-Rodríguez; Soo Aleman; Nathalie Ganne-Carrié; Roberta D'Ambrosio; Stanislas Pol; Maria Trapero-Marugan; Raoel Maan; Ricardo Moreno-Otero; Vincent Mallet; Rolf Hultcrantz; Ola Weiland; Karoline Rutter; Vito Di Marco; Sonia Alonso; Savino Bruno; Massimo Colombo; Robert J de Knegt; Bart J Veldt; Bettina E Hansen; Harry L A Janssen
Journal:  J Hepatol       Date:  2016-10-22       Impact factor: 25.083

7.  Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.

Authors:  Heiner Wedemeyer; Cihan Yurdaydin; Svenja Hardtke; Florin Alexandru Caruntu; Manuela G Curescu; Kendal Yalcin; Ulus S Akarca; Selim Gürel; Stefan Zeuzem; Andreas Erhardt; Stefan Lüth; George V Papatheodoridis; Onur Keskin; Kerstin Port; Monica Radu; Mustafa K Celen; Ramazan Idilman; Kristina Weber; Judith Stift; Ulrike Wittkop; Benjamin Heidrich; Ingmar Mederacke; Heiko von der Leyen; Hans Peter Dienes; Markus Cornberg; Armin Koch; Michael P Manns
Journal:  Lancet Infect Dis       Date:  2019-03       Impact factor: 25.071

8.  Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis.

Authors:  Mathias Jachs; Teresa Binter; Caroline Schmidbauer; Lukas Hartl; Michael Strasser; Hermann Laferl; Stephanie Hametner-Schreil; Alexander Lindorfer; Kristina Dax; Rudolf E Stauber; Harald H Kessler; Sebastian Bernhofer; Andreas Maieron; Lorin Loacker; Simona Bota; Isabel Santonja; Petra Munda; Mattias Mandorfer; Markus Peck-Radosavljevic; Heidemarie Holzmann; Michael Gschwantler; Heinz Zoller; Peter Ferenci; Thomas Reiberger
Journal:  United European Gastroenterol J       Date:  2021-12-07       Impact factor: 4.623

9.  Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.

Authors:  Pauline Arends; Milan J Sonneveld; Roeland Zoutendijk; Ivana Carey; Ashley Brown; Massimo Fasano; David Mutimer; Katja Deterding; Jurriën G P Reijnders; Ye Oo; Jörg Petersen; Florian van Bömmel; Robert J de Knegt; Teresa Santantonio; Thomas Berg; Tania M Welzel; Heiner Wedemeyer; Maria Buti; Pierre Pradat; Fabien Zoulim; Bettina Hansen; Harry L A Janssen
Journal:  Gut       Date:  2014-07-10       Impact factor: 23.059

10.  High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta.

Authors:  Raffaella Romeo; Barbara Foglieni; Giovanni Casazza; Marta Spreafico; Massimo Colombo; Daniele Prati
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.